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Background: Stickler syndrome is a connective tissue disorder characterized by ocular, skeletal, orofacial and
auditory defects. It is caused by mutations in different collagen genes, namely COL2A1, COL11A1 and COL11A2
(autosomal dominant inheritance), and COL9A1 and COL9A2 (autosomal recessive inheritance). The auditory
phenotype in Stickler syndrome is inconsistently reported. Therefore we performed a systematic review of the
literature to give an up-to-date overview of hearing loss in Stickler syndrome, and correlated it with the genotype.
Methods: English-language literature was reviewed through searches of PubMed and Web of Science, in order to
find relevant articles describing auditory features in Stickler patients, along with genotype. Prevalences of hearing
loss are calculated and correlated with the different affected genes and type of mutation.
Results: 313 patients (102 families) individually described in 46 articles were included. Hearing loss was found in
62.9%, mostly mild to moderate when reported. Hearing impairment was predominantly sensorineural (67.8%).
Conductive (14.1%) and mixed (18.1%) hearing loss was primarily found in young patients or patients with a palatal
defect. Overall, mutations in COL11A1 (82.5%) and COL11A2 (94.1%) seem to be more frequently associated with
hearing impairment than mutations in COL2A1 (52.2%).
Conclusions: Hearing impairment in patients with Stickler syndrome is common. Sensorineural hearing loss
predominates, but also conductive hearing loss, especially in children and patients with a palatal defect, may occur.
The distinct disease-causing collagen genes are associated with a different prevalence of hearing impairment, but
still large phenotypic variation exists. Regular auditory follow-up is strongly advised, particularly because many
Stickler patients are visually impaired.
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Stickler syndrome or hereditary progressive arthro-
ophthalmopathy [1] (ORPHA828) is a connective tissue
disorder affecting about 1/7,500 to 1/9,000 newborns
[2]. It is characterized by ocular, skeletal, orofacial, and
auditory abnormalities. Typical features include vitreor-
etinal degeneration, high-grade myopia, retinal detach-
ment, premature osteoarthritis, midfacial hypoplasia,
cleft palate and hearing loss [3,4].
Stickler syndrome is subdivided into several subtypes,
based on its underlying genetic collagen defect. At
present, defects in three different collagen genes have
been found in patients with autosomal dominant Stickler* Correspondence: frederic.acke@ugent.be
1Department of Otorhinolaryngology, 1P1, Ghent University / Ghent
University Hospital, De Pintelaan 185, Ghent 9000, Belgium
Full list of author information is available at the end of the article
© 2012 Acke et al.; licensee BioMed Central Lt
Commons Attribution License (http://creativec
reproduction in any medium, provided the orsyndrome. Type I Stickler syndrome (STL1) is associated
with mutations in the COL2A1 gene encoding type II
collagen [5], while mutations in COL11A1 and COL11A2
encoding type XI collagen, are associated with type II
(STL2) [6] and type III Stickler syndrome (STL3) [7] re-
spectively. Autosomal recessive Stickler syndrome has
been described in some families with mutations in
COL9A1 (STL4) [8] and COL9A2 (STL5) [9] encoding
type IX collagen.
Phenotypic distinction between patients with muta-
tions in different causative genes is possible to a certain
degree. For example, STL3 does not exhibit ocular ab-
normalities, as COL11A2 is not expressed in the vitreous
[10]. Another example is the vitreous anomaly, which is
mostly ‘membranous’ in STL1 and ‘beaded’ in STL2 [6].
However, large phenotypic difference, not explainedd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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family or within unrelated families carrying the same
mutation, clinical expression shows high variability [11].
In 1965, Stickler et al. described a family with joint
manifestations and progressive myopia, associated with
retinal detachment in the first decade of life and result-
ing in blindness [1]. In an additional report, mild sen-
sorineural hearing impairment was added to the features
typical of this syndrome [12]. Subsequently, hearing
impairment has commonly been reported as a symptom
of Stickler syndrome, though detailed descriptions are
scarce and few studies are primarily focused on the
auditory phenotype. Hearing loss in STL1 seems to be
present in about 60% of affected persons and is likely to
be sensorineural [13,14]. STL2 and STL3 are associated
with hearing loss occurring more frequently and being
more severe [13]. The pathogenesis of this sensorineural
hearing loss is not well understood. Associated findings
are a hypermobile tympanic membrane [14], and cleft
palate resulting in middle ear effusion and conductive
hearing loss.
Because of the large interfamilial and intrafamilial
phenotypic variability observed in Stickler patients, clini-
cians are unfortunately unable to predict whether their
patients will develop hearing loss. In this article, we aim to
review the literature about hearing impairment in all types
of Stickler syndrome. The auditory features of patients
found by systematic review is described and prevalences,
obtained through meta-analysis, are provided. Hearing loss
is also linked to the causal gene, mutation type and muta-
tion effect in order to find correlations. This article offers
an up-to-date overview of hearing loss in Stickler syn-
drome, correlated with the genotype.
Materials and methods
Search strategy
A systematic review was performed in order to analyze
the auditory features in Stickler syndrome. We intended
to find all papers describing the phenotype with regard
to hearing in Stickler patients, along with their genotype.
Relevant articles were searched using the electronic
databases of PubMed and Web of Science from incep-
tion to 31 July 2012. Considering the different notations
(e.g. Stickler syndrome vs. Stickler’s syndrome), follow-
ing search strings were used: “stickler*” and “arthro-
ophthalmopath* OR arthroophthalmopath*”. To exclude
non-relevant articles, the queries were restricted to title/
abstract in Pubmed and topic in Web of Science. Refer-
ence lists of the retrieved articles were hand-searched
for additional papers. A bibliography with the citations
retrieved from the abovementioned searches was created
using EndNote X4 (Thomson Reuters, New York, USA).
Duplicates and non-English articles were removed both
automatically and manually, as well as short conferenceproceedings. One investigator (FA) conducted this first
selection of articles, under the auspices of the principal
investigators (EDL, ID), in order to find articles for
review purposes.
To perform a meta-analysis, the eligibility of papers was
assessed based on two main inclusion criteria: the indica-
tion of the presence or absence of hearing impairment in
Stickler and Stickler-like patients and the finding of a
causative mutation. Probable Marshall phenotype and
autosomal recessive otospondylomegaepiphyseal dysplasia
(OSMED) patients were excluded, as well as patients in
whom only linkage to a gene was demonstrated. In case
of doubt, mutual agreement between the authors was
achieved.
Statistical analysis
The following data, if available, were extracted from arti-
cles meeting the inclusion criteria: study characteristics
(authors, year of publication, study design and methods,
original data or described elsewhere), patient attributes
(family and age, relevant comorbidities), hearing features
(hearing impairment, type and severity of hearing loss,
additional auditory data, palatal defects) and mutation
(mutated gene, mutation type and location, mutation
effect). When a patient or family was described in differ-
ent papers, the most informative paper was used for data
collection.
Calculations were performed using SPSS version 19
(SPSS Inc., Chicago, USA). Where appropriate, statistical
tests were used to assess statistical significance. Exons of
COL2A1 were numbered according to the GenBank
database [GenBank:L10347]. In order to avoid selection
bias (proportionally greater importance of larger fam-
ilies), some calculations were repeated in an analysis
where all families were equally weighted. In the subtypes
of Stickler syndrome where sufficient audiograms of dif-
ferent patients could be collected, an average audiogram
or even an age-related typical audiogram (ARTA) of the
respective subtype was calculated.
The study was conducted taking into account the
instructions of the PRISMA statement for reporting sys-
tematic reviews [15] and of the MOOSE group for report-
ing a meta-analysis of observational studies [16].
Results
Search results
A flow diagram of the search process is depicted in
Figure 1. For review purposes, 451 articles were read
to extract interesting data described in the discussion.
Ultimately, 46 articles were included in the meta-analysis
(see Additional file 1: Table S1 for description of the
included articles) [3,5,8,9,11,17-57]. Seven papers that ful-
filled the inclusion criteria were withheld because of differ-
ent reasons. Five of them contained data of patients being
Figure 1 PRISMA flow diagram, showing the overview of the search process. Schematic overview of the various steps involved in the
search process, according to the PRISMA guidelines. We read 451 articles about Stickler syndrome, whose content, if relevant, could be included
in the discussion. Data from 46 articles, meeting the inclusion criteria of the meta-analysis, are used to provide accurate prevalences about
hearing loss in the results section of this article.
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one reported a patient suffering from a second genetic dis-
order that could as well result in hearing loss [61], and
hearing impairment in another one was unclear [62]. Qual-
ity of the included papers was assessed (Additional file 1:
Table S1), but none of them were rejected based on quality
properties alone, in order to obtain a large population in
which it is possible to draw firm conclusions. In the 46
included articles, a total of 313 individual patients of 102
families were found to meet the inclusion criteria. Nine
additional families with phenotypic and genotypic informa-
tion, but without individual data, were added, resulting in
111 different Stickler families.
Auditory phenotype in Stickler syndrome
Mean age of the individual Stickler patients was 26.4 years
(standard deviation 19.49, age was given in 221 patients),
and gender distribution was 55.2% female versus 44.8%
male persons (gender was provided in 210 patients).
Hearing loss was reported in 197 of the 313 patients
(62.9%, Figure 2). In 177 cases, the type of hearing loss wasmentioned. In this group 120 patients (67.8%) showed a
pure sensorineural hearing loss. Mixed hearing loss was
present in 32 persons (18.1%), and 25 patients (14.1%) suf-
fered from conductive hearing loss. Consequently, a con-
ductive component (conductive and mixed hearing loss)
was present in 32.2% of the hearing-impaired patients.
Figure 3 shows the distribution of prevalence and type of
hearing loss among different age groups (age was available
in 221 patients). When splitting up the hearing-impaired
population in which age is available into a group of chil-
dren (below 18 years) and a group of adults (aged 18 and
older), hearing loss included a conductive component in
46.6% (27/58) in the younger group versus 23.3% (20/86)
in the older group (p = 0.004, Fisher exact test). Gender
did not significantly alter the prevalence of hearing loss,
not even at high age (p = 0.31 for the whole group, Fisher
exact test). Regarding severity, hearing loss was mild in
44.6%, moderate in 36.6% and severe in 18.8% of the sub-
jects, although it is often not clear which definitions for
severity were applied. No profound hearing loss was
observed. In patients with mixed hearing loss, severity was
Figure 2 The prevalence and type of hearing loss in Stickler syndrome. The percentages of the 313 included Stickler patients without and
with hearing loss are displayed. Of the hearing-impaired patients, a subdivision into conductive, mixed and sensorineural hearing loss is provided.
The group of hearing-impaired patients in which the type was not mentioned (6.4% of the total population), was proportionally divided among
the three hearing loss groups.
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be moderate at worst.
A palatal defect (cleft palate, submucous cleft, high-
arched palate) was present in 42.6% (121/284) of the stud-
ied population. Of the patients with a palatal defect, 73.6%
(89/121) were hearing-impaired, compared to 54.0% (88/
163) without palatal defect (p < 0.001, Fisher exact test). As
seen in Table 1, this difference can largely be attributed to
the higher prevalence of conductive and mixed hearing
loss, while the percentage of sensorineural hearing loss is
comparable between the two groups.
Auditory phenotype in different Stickler genotypes
STL1 occurred in 224 cases (71.6%), while this was 40
(12.8%) for STL2, 34 (10.9%) for STL3, 7 (2.2%) for STL4
and 8 (2.6%) for STL5. For each Stickler gene, the distinct
percentage and type of hearing loss is shown in Figure 4.0% 
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Figure 3 Prevalences of hearing phenotype in Stickler patients, divide
each age group can be derived from this diagram. The group of hearing-im
proportionally divided among the three hearing loss groups.Severity of hearing loss was mostly reported to be mild to
moderate for STL1, STL2 and STL5. In STL3 and STL4,
predominantly moderate and severe hearing loss was
found respectively. An ARTA for STL3 and an average
audiogram for STL4 are provided in Figure 5, as well as an
ARTA for Stickler syndrome in general. Palatal defects
were present in 44.3%, 48.7% and 44.8% in STL1, STL2
and STL3, respectively. Patients with a collagen IX muta-
tion (STL4 and STL5) did not exhibit palatal defects.
The mutations of 36 STL1 patients were expected to re-
sult in a dominant-negative effect, while these of 174 STL1
patients were supposed to induce nonsense-mediated
decay (mutation effect was available in 210 STL1 patients).
Hearing loss was present in 47.2% of the first group versus
52.9% of the second (p = 0.59, Fisher exact test), and a pal-
atal defect occurred in 16.7% versus 46.9% (p = 0.002,
Fisher exact test). No statistical significance was observed42 
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d into age groups. The percentages of hearing loss and its type for
paired patients in which the type was not mentioned (6.4%), was
Table 1 Prevalence and type of hearing loss in patients
with and without palatal defect
Palatal
defect
(n = 121)
No palatal
defect
(n = 163)
p value
No hearing loss 26.4% 46.0% <0.001
Conductive hearing loss 13.6% 4.2% 0.008
Mixed hearing loss 20.0% 6.3% <0.001
Sensorineural hearing loss 40.0% 43.5% 0.544
This table shows the percentages of each type of hearing phenotype for
patients with and without palatal defect separately. Palatal defects include
cleft palate, submucous cleft and high-arched palate. The group of hearing-
impaired patients in which the type was not mentioned, was proportionally
divided among the three hearing loss groups. Stickler patients with a palatal
defect exhibit significantly more hearing loss, and this can be attributed to the
higher number of patients with conductive and mixed hearing loss.
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(exon/intron number) and the presence of hearing loss
(p = 0.44, Mann–Whitney U test; mean exon number of
26.0 when hearing loss is absent vs. 28.8 when present),
but differences were seen between mutation location and
palatal defects (p = 0.01, Mann–Whitney U test; mean
exon number of 24.4 when palatal defect is absent vs. 30.4
when present).Auditory phenotype and genotype in family study
When the 111 different families are equally weighted,
regardless of the number of affected family members,
the prevalence of hearing loss was 60.1%. Within these
hearing-impaired subjects, the percentages of sensori-
neural, mixed and conductive hearing loss were 60.4%,
18.3% and 21.3%, respectively. The prevalence of palatal0% 10% 20% 30% 40% 50% 60% 
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Figure 4 Hearing phenotype in distinct Stickler types. The percentages
(according to the affected gene) are shown in this figure. The group of hea
was proportionally divided among the three hearing loss groups.defects was 51.5%. STL1 occurred in 85 families (76.6%),
while this was 17 (15.3%) for STL2, 5 (4.5%) for STL3,
3 (2.7%) for STL4 and 1 (0.9%) for STL5.
Discussion
Hearing loss is a common feature in Stickler syndrome,
expressed in 63% of all patients. About two-thirds of
these hearing-impaired patients express a purely sensori-
neural loss. This prevalence increases with advancing
age, most probably not only due to age-related hearing
loss. Conductive and mixed hearing loss is mostly found
in children with Stickler syndrome and in patients with
a history of a palatal defect, but can also be present in
adults. These results are consistent with those of other
authors studying hearing features in a large group of
Stickler patients [14,63]. As the distinct disease-causing
collagen genes in Stickler syndrome lead to a different
auditory phenotype, hearing features are described for
the involved genes separately.
About 75% of all Stickler patients have type I Stickler
syndrome, caused by mutations in COL2A1. This type
has the best prognosis concerning hearing: 52.2% of the
affected persons exhibit hearing loss, which is mostly
sensorineural. As in the other dominant Stickler types,
conductive and mixed hearing loss may also be present,
especially in young children and with a palatal defect.
The sensorineural hearing loss is often reported to affect
mainly the higher frequencies. Progression of hearing
impairment is described, but it is unclear whether the
high-frequency hearing loss in STL1 progresses beyond
presbyacusis. It is generally mild to moderate and does
not evolve to severe hearing impairment.70% 80% 90% 100% 
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of hearing loss and its type for each type of Stickler syndrome
ring-impaired patients in which the type was not mentioned (6.4%),
Figure 5 Typical audiograms for Stickler syndrome in general, and for STL3 and STL4. A) ARTA for Stickler patients in general (without
genetic subclassification), based on the detailed audiometric results in 44 patients [14]. Mean air conduction thresholds of both ears are shown.
B) ARTA for type III Stickler syndrome, based on the detailed audiometric results in 18 STL3 patients (52 different measurements) [17,53]. Air
conduction thresholds of the best ear are shown, unless in patients where an air-bone gap was present, in which bone conduction of the best
ear is shown. C) Average audiogram for type IV Stickler syndrome, based on the detailed audiometric results in 7 STL4 patients (median age 15y)
[8,41]. Air conduction thresholds of the best ear are shown.
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which may explain why mutations in this gene can cause
hearing loss [64]. Stickler syndrome is just one of the
clinical expressions that belongs to the spectrum of type
II collagenopathies, ranging from the lethal achondro-
genesis type II, to mild forms of solely ocular or skeletal
manifestations. Some of these expressions are also asso-
ciated with hearing loss. However, large variability, inter-
familial as well as intrafamilial, exists. Our study failed
to find significant differences in STL1 hearing loss
due to mutation effect and location. Therefore, it can
be suggested that modifier genes and environmental
factors may also play a role in the development of
hearing loss.
Type II Stickler syndrome (COL11A1) is the second most
common type of Stickler syndrome. It is estimated to be
present in about 15% of the probands with Stickler syn-
drome. Hearing loss is found in 82.5% of these patients;
most of them have sensorineural loss, but again, also con-
ductive and mixed hearing impairment have been described.
Hearing loss in STL2 seems to be more pronounced than in
STL1, and is already apparent at young age. It is not clear
whether the higher frequencies are predominantly affected
and whether or not the hearing loss progresses with age.
Marshall syndrome is allelic with STL2 and both diseases
show considerable overlap. Most of the Marshall patients
also develop early-onset, high-frequency sensorineural
hearing loss progressing to severe hearing impairment at
older ages.
Type XI collagen is associated with type II collagen and
hybridization of their gene products can be found in thelateral wall of the developing mouse cochlea. It is suggested
that mutations in COL11A1 may influence hearing due to
their effects on the formation and function of the tectorial
membrane [65]. Until now, it is not yet clarified how muta-
tions in this gene can cause the above-mentioned type of
hearing loss. However, although not quantitatively import-
ant in the inner ear, COL11A1 protein seems to be crucial
for normal hearing.
In type III Stickler syndrome (COL11A2), hearing loss
was found in 94.1% of the patients. It can even be sug-
gested that all STL3 patients have some degree of hearing
loss, because the two subjects not exhibiting hearing pro-
blems, were not audiometrically tested [51]. Sensorineural
hearing impairment is, as in STL1 and STL2, most preva-
lent, and seems to be more pronounced in the middle and
higher frequencies. However, there is no typical audiomet-
ric configuration and a conductive component may also be
present [17]. Hearing loss in STL3 is likely to have a child-
hood onset and does not or just slightly progress; its sever-
ity is mostly moderate.
Mutations in COL11A2 may also result in non-
syndromic hearing loss as in DFNA13 and DFNB53.
Hearing impairment in DFNA13 is non-progressive,
probably prelingual, and represented by a U-shaped to
slightly down-sloping audiogram [66]. Interestingly, one
family with DFNA13 seemed to be protected against
presbyacusis [67], which might also be present in type
III Stickler syndrome [53]. DFNB53-related hearing im-
pairment results in a prelingual, severe, U-shaped audio-
gram [68]. Autosomal recessive OSMED is caused by
mutations in COL11A2 as well. This syndrome is
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enlarged epiphyses, shortness of the limbs and orofacial
features comparable to those of Stickler syndrome [69].
Previous studies revealed the disruption of collagen
fibrils within the tectorial membrane to be the only
observed morphological inner ear change of COL11A2
−/− mice, resulting in a frequency-independent, cochlear
loss of 30-50 dB [66,70]. Consequently, collagen type XI
is important to maintain the tectorial membrane integ-
rity, as both COL11A1 and COL11A2 mutations may
cause hearing loss due to changed morphology of this
inner ear structure.
Four different families with autosomal recessive Stick-
ler syndrome have been described, all exhibiting a muta-
tion in genes encoding type IX collagen [8,9,41]. The
involved patients showed a similar pattern of hearing
impairment: a slightly progressive sensorineural hearing
loss with early onset, more pronounced at higher fre-
quencies. Severity was moderate to severe in STL4
(COL9A1) and mild to moderate in STL5 (COL9A2).
None of these patients showed palatal defects.
These results are consistent with animal studies, which
demonstrated type IX collagen, in addition to type XI
collagen, as an important factor in maintaining the in-
tegrity of collagen fibers in the tectorial membrane [71].
Type IX collagen knock-out mice showed progressive
hearing loss and morphological changes of the tectorial
membrane, starting in the basal turn of the cochlea and
progressing towards the apical turn [72]. This is in line
with the observed hearing loss in recessive Stickler syn-
drome: progressive and initially more pronounced at
higher frequencies.
Besides Stickler syndrome, mutated type IX collagen can
also result, inter alia, in multiple epiphyseal dysplasia
(MED), a skeletal dysplasia not associated with hearing loss.
However, MED has been attributed to heterozygous splice
site mutations in type IX collagen genes, resulting in in-
frame exon skipping situated in the third collagenous do-
main (COL3) and effectuating a dominant-negative effect
[41,73]. In contrast, the mutations found in STL4 and
STL5 are more spread out over the gene and are supposed
to result in nonsense-mediated decay.
Another, rather specific, auditory finding in Stickler syn-
drome is hypermobility of the tympanic membrane, mea-
sured by tympanometry. In up to 46% of Stickler patients,
type AD tympanograms were obtained [3,11,14]. Most of
these patients probably had STL1, because tympanic hyper-
mobility was less seen in STL2 patients [74]. Hypermobile
middle ear system may be the result of frequent otitis
media with ventilation tubes and/or tympanic perforations,
but the collagen defect in STL1 may also contribute. In-
deed, type II collagen is observed in the ossicular joints [75]
and is the most abundant collagen of the tympanic lamina
propria [76].In Stickler patients, language and speech may be
affected by hearing impairment and by the typical facial
morphology, including cleft palate, especially if these pro-
blems are not recognized early and optimally treated.
However, speech audiometry showed perception and dis-
crimination scores consistent with the obtained pure tone
thresholds [17].
Little attention is paid to the vestibular system of Stick-
ler patients. Ocular and skeletal manifestations can con-
tribute to instability complaints and may interfere with
some of the balance tests [14]. Five tested children and 1
adult have been identified as having abnormal peripheral
vestibular function combined with hearing loss [77]. In
their review, Admiraal et al. stated that Stickler patients
rarely complain about vestibular symptoms, though ves-
tibular deficits may be objectified [13]. Future research
should also focus on the vestibular system, as this may
render novel insight into the pathophysiology of the
syndrome.
Temporal bone imaging in Stickler syndrome mostly
does not reveal middle or inner ear structural anomal-
ies (5 cases mentioned by Rai et al. [78], 19 cases in
Szymko-Bennett et al. [14]). In sporadic cases, ossicular
defects [4] and fixations [21] were reported. Again, more
studies need to be performed to draw strong conclusions
about temporal bone anomalies in Stickler syndrome.
Conductive hearing loss in adults is sporadically reported
and can be due to stapes ankylosis [21], chronic ear disease
resulting in mastoidectomy surgery [17,43], and eustachian
tube dysfunction, predominantly in patients with a history
of cleft palate. With the latter in mind, clinicians should
also be aware of cholesteatoma development in Stickler
patients.
Overall, when interpreting these results, some com-
ments have to be made. A family analysis was performed
in order to avoid bias due to the greater importance of
families in which a large number of affected family mem-
bers are described. When the different families are equally
weighted, only minor differences could be found concern-
ing the auditory phenotype. To avoid reporting bias, we
also included papers in which hearing features were not
extensively described or studied. However, quality analysis
of the studied articles revealed that hearing loss seems to
be found more in studies with auditory testing compared
to history alone. Consequently, we confirm that clini-
cians cannot rely on patients’ history of hearing capacity
alone, and that regular hearing tests in Stickler patients
are recommended, regardless of symptom reporting [79].
Future research should focus on progression of hearing loss
and the audiometric configuration, especially the presence
and practical influence of high-frequency sensorineural loss.
These results may even contribute in unravelling the patho-
physiology of presbyacusis. Novel Stickler studies should
take into account age-related hearing loss, as few studies to
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used. It would also be interesting to study other relevant
topics, such as imaging of the middle and inner ear struc-
tures, and functioning of the vestibular system, as these are
not well described in literature.
Conclusions
Hearing loss is a common finding in Stickler syndrome,
affecting more than half of the patients. Sensorineural
hearing loss predominates, but conductive and mixed
hearing loss may also be present, especially in young
children and in patients with an associated palatal de-
fect. There are differences in prevalence of hearing loss
for the different types of Stickler syndrome and each
genotype shows a different pattern of hearing loss. Hear-
ing loss in STL1 is present in half of the patients and is
usually mild to moderate, while hearing impairment in
STL2 and STL3 is more common, more severe, and
present at younger age. However, we have to be aware of
large phenotypic variation. Given the high prevalence of
hearing loss in Stickler patients, referral for hearing
assessment and regular auditory follow-up is required
upon diagnosis. If hearing impairment is detected, site of
lesion testing will guide treatment options, such as ven-
tilation tube insertion and hearing aid fitting. Close
attention to the hearing system is particularly important
because most of the patients are already visually
impaired.
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